Common Diabetes Drug Shows Promise for Preventing Vision Loss

Breakthrough Discovery Links Metformin to Eye Protection

A widely prescribed diabetes medication may offer unexpected protection against one of the leading causes of blindness in older adults. Researchers found that people with diabetes who were over 55 and taking metformin were 37% less likely to develop the intermediate stage of age-related macular degeneration (AMD) over a five-year period compared to those not taking the drug.

The findings emerged from a study of 2,000 patients who attended routine diabetic eye disease screenings in Liverpool over five years. Age-related macular degeneration affects approximately 11 million people in the United States, with that number expected to double by 2050 due to the aging population. If left untreated, AMD is the leading cause of vision loss in people over age 60.

How This Common Drug Works Beyond Blood Sugar

Metformin is described as the first-line treatment for type 2 diabetes, reducing glucose production in the liver along with other effects that benefit diabetes. However, the drug also has anti-aging effects, including being antioxidant, anti-inflammatory, and stimulating housekeeping functions and energy production in cells.

Some studies have found that diabetic patients taking metformin have a lower incidence of age-related diseases such as cardiovascular disease, cancer, and cognitive decline compared to non-diabetic individuals or diabetic patients not on metformin. The drug has been FDA approved for 30-40 years and has a very good safety profile, with substantial evidence that it may be helpful in other parts of the aging process.

Growing Evidence Spans Multiple Studies

This discovery builds on a growing body of research. Previous studies published in JAMA Ophthalmology showed that metformin reduced the odds of developing AMD, with protective effects appearing even stronger in people without diabetes than in those with the condition. A comprehensive meta-analysis revealed a significant reduction in the odds of AMD among metformin users, with a pooled odds ratio of 0.86.

Research involving patients without diabetes found that metformin exposure was associated with reduced odds of developing any AMD, specifically in certain dosing ranges, with similar protective effects for dry AMD. The association appears to be dose dependent, with the greatest benefit occurring at low to moderate doses.

Path Forward Requires Careful Validation

Experts emphasize that more studies are needed to confirm the association and that metformin should not yet be prescribed specifically for treating age-related macular degeneration. The current research was observational, meaning it shows a link between the drug and eye health but does not prove metformin was the direct cause of the improvement.

Although current evidence suggests a potential protective role of metformin in AMD, all studies showing an effect have been observational and thus subject to bias, with randomized clinical trials needed to determine effectiveness. If proven effective, metformin's potential to serve as a treatment for AMD could significantly reduce the burden of vision loss, offering a cost-effective and widely accessible solution. Given its low cost, wide availability, and favorable safety profile, metformin could play a substantial role in AMD management, especially considering the paucity of alternative treatment options.